A chapter published in Placebo Effects Through the Lens of Translational Research explores the possibility of open-label placebos as a psychotherapy and how psychotherapy might benefit from its use.
Placebos, known for their wide-ranging forms and impacts, are a complex and multifaceted concept in medical and psychological treatments. Traditionally perceived as inert substances used in pharmacological trials, placebos have evolved to encompass various forms such as pills, sprays, surgeries, and even exercise or wine. Their effects are not limited to any specific medical condition; they are observed in chronic and acute pain, insomnia, depression, PTSD, and schizophrenia, among other disorders.
Jens Gaab argues that this extensive range makes it challenging to definitively categorize any treatment as devoid of placebo effects. The definition of placebo is complicated by the fact that it can induce specific physiological effects, active treatments can function as placebos, and a placebo can still be considered as such even without any observable effect. The difficulty arises when trying to extend this concept to non-pharmacological treatments like psychotherapy, which inherently involves psychological effects.
The interplay between psychotherapy and placebo is particularly intricate. Historical references highlight the longstanding association between psychotherapy and placebo-like concepts. The debate over psychotherapy’s efficacy, often showing marginal benefits over control conditions, underscores the challenge in differentiating specific treatment effects from placebo responses. Notably, certain therapies initially designed as control conditions in clinical trials have later been recognized as effective treatments in their own right.
The mechanisms underlying placebos and psychotherapy, such as expectancy effects and the therapeutic alliance, further blur the distinction. Both interventions have been described as “meaning” interventions, suggesting a commonality. This leads to the question of whether psychotherapy is essentially a sophisticated form of placebo, or whether it possesses unique therapeutic mechanisms.
To address this, an “ethical” definition of placebo is proposed, emphasizing the deceptive administration of a treatment consisting solely of incidental treatment constituents. This perspective allows for a treatment to be categorized as a placebo based on the intent and context of its administration, rather than its physical properties or effects. This definition also implies that openly administered placebos, which are transparent about their nature, would not qualify as placebos but rather as legitimate therapeutic interventions.
Openly administered placebos challenge traditional views of placebos by demonstrating efficacy even when their placebo nature is disclosed. In the context of psychotherapy, this approach would align with the principles of informed consent and patient autonomy. However, there is a noticeable reluctance within the psychotherapy community to fully embrace this openness, particularly when it comes to disclosing the mechanisms of action of therapeutic interventions.
While psychotherapy is not inherently a placebo, it could function as one in certain contexts, especially when the therapeutic factors are not fully disclosed or are deceptive. The ethical application of psychotherapy aligns closely with the principles of openly administered placebos, emphasizing transparency and patient empowerment. Gaab argues that this approach could enhance the ethical standing of psychotherapy and optimize its therapeutic potential.
The chapter, “Why psychotherapy is an open-label placebo and open-label placebos are psychotherapy”, was authored by Jens Gaab.
